Monitoring of Hemostasis and Management of Anticoagulant Thromboprophylaxis in Pregnant Women with Increased Risk of Fetal Loss

Abstract

Physiological prothrombotic changes during pregnancy and the postpartum period, along with other preexisting maternal risk factors, increase the risk of both venous thromboembolism (VTE) and adverse pregnancy outcomes. Pregnancy complications that develop due to placental insufficiency as a result of inappropriate activation of coagulation are present in more than 5% of pregnancies and can contribute to significant maternal morbidity and mortality. Therefore, anticoagulant prophylaxis in women with congenital and acquired thrombophilic conditions should be actively considered. According to the Guidelines of American College of Chest Physicians, the use of low-molecular-weight heparin is suggested for prophylaxis of VTE and pregnancy complications in high-risk pregnant women. However, personalized refinements of such thromboprophylaxis remains unspecified, despite the necessity of better targeted recommendations for life-threatening conditions. We, therefore, review the possibilities of longitudinal monitoring and comprehensive assessment of changes in hemostasis in the group of high-risk pregnant women, which can then be used for early prediction and individualization of the optimal anticoagulant thromboprophylaxis of pregnancy complications. Simultaneously, we present our single-center experience with such monitoring and our first series of results.

Keywords

high-risk pregnancy - fetal loss - anticoagulant prevention - monitoring of hemostasis - thrombosis

• References

• 1 Dawood F. Pregnancy and Thrombophilia. J Blood Disorders Transf 2013; 4: 5
• 2 Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009; 23 (5) 225-229
• 3 Eichinger S. D-dimer testing in pregnancy. Semin Vasc Med 2005; 5 (4) 375-378
• 4 Rosenkranz A, Hiden M, Leschnik B , et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost 2008; 99 (2) 331-337
• 5 Sarig G, Blumenfeld Z, Leiba R, Lanir N, Brenner B. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 2005; 94 (5) 980-985
• 6 Bremme K, Lind H, Blombäck M. The effect of prophylactic heparin treatment on enhanced thrombin generation in pregnancy. Obstet Gynecol 1993; 81 (1) 78-83
• 7 Mastrolia SA, Mazor M, Loverro G, Klaitman V, Erez O. Placental vascular pathology and increased thrombin generation as mechanisms of disease in obstetrical syndromes. PeerJ 2014; 2: e653
• 8 Duffett L, Rodger M. LMWH to prevent placenta-mediated pregnancy complications: an update. Br J Haematol 2015; 168 (5) 619-638
• 9 Rodger MA, Langlois NJ, de Vries JI , et al. Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). Syst Rev 2014; 3: 69
• 10 Abu-Heija A. Thrombophilia and Recurrent Pregnancy Loss: Is heparin still the drug of choice?. Sultan Qaboos Univ Med J 2014; 14 (1) e26-e36
• 11 Vucić N, Frleta M, Petrović D, Ostojić V. Thrombophilia, preeclampsia and other pregnancy complications [in Croatian]. Acta Med Croatica 2009; 63 (4) 297-305
• 12 Sultan AA, Tata LJ, West J , et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 2013; 121 (19) 3953-3961
• 13 Bates SM, Greer IA, Middeldorp S , et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S-e736S
• 14 Guimicheva B, Czuprynska J, Arya R. The prevention of pregnancy-related venous thromboembolism. Br J Haematol 2015; 168 (2) 163-174
• 15 Scharf RE, Pestka MA. Pharmacological thromboprophylaxis in gynecology and obstetrics [in German]. Hamostaseologie 2014; 34 (4) 277-288 , quiz 289
• 16 Aracic N, Roje D, Drmic Hofman I, Capkun V, Stefanovic V. Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome. J Matern Fetal Neonatal Med 2015; 28 (3) 306-310
• 17 Buyue Y, Misenheimer TM, Sheehan JP. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. J Thromb Haemost 2012; 10 (10) 2086-2098
• 18 Hirsh J, Warkentin TE, Shaughnessy SG , et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1, Suppl): 64S-94S
• 19 Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23 (Suppl. 01) 103-106
• 20 Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000; 26 (Suppl. 01) 5-21
• 21 Obi AT, Diaz JA, Ballard-Lipka NL , et al. Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner. J Vasc Surg Venous Lymphat Disord 2014; 2 (4) 441-450.e1
• 22 Iwase H, Ekser B, Zhou H, Dons EM, Cooper DK, Ezzelarab MB. Platelet aggregation in humans and nonhuman primates: relevance to xenotransplantation. Xenotransplantation 2012; 19 (4) 233-243
• 23 Quaranta M, Erez O, Mastrolia SA , et al. The physiologic and therapeutic role of heparin in implantation and placentation. PeerJ 2015; 3: e691
• 24 Allahbadia GN. Low-Molecular-Weight Heparin (LMWH) in Women with Repeated Implantation Failure. J Obstet Gynaecol India 2012; 62 (4) 381-383
• 25 Casele HL. The use of unfractionated heparin and low molecular weight heparins in pregnancy. Clin Obstet Gynecol 2006; 49 (4) 895-905
• 26 Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy—how safe are they?. Curr Opin Obstet Gynecol 2007; 19 (6) 573-577
• 27 Manresa Ramón N, Nájera Pérez MD, Page del Pozo MÁ, Sánchez Martínez I, Sánchez Catalicio MdelM, Roldán Schilling V. Set up of a protocol for heparin use in special patients [in Spanish]. Farm Hosp 2014; 38 (2) 135-144
• 28 Mutlu I, Mutlu MF, Biri A, Bulut B, Erdem M, Erdem A. Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history. Blood Coagul Fibrinolysis 2015; 26 (3) 267-273
• 29 Dentali F, Grandone E, Rezoagli E, Ageno W. Efficacy of low molecular weight heparin in patients undergoing in vitro fertilization or intracytoplasmic sperm injection. J Thromb Haemost 2011; 9 (12) 2503-2506
• 30 Misra D, Aledort L. Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy. Am J Hematol 2011; 86 (2) 235
• 31 Sephton V, Farquharson RG, Topping J , et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101 (6) 1307-1311
• 32 Patel JP, Hunt BJ. Where do we go now with low molecular weight heparin use in obstetric care?. J Thromb Haemost 2008; 6 (9) 1461-1467
• 33 James A ; Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011; 118 (3) 718-729
• 34 Shapiro NL, Kominiarek MA, Nutescu EA, Chevalier AB, Hibbard JU. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. Pharmacotherapy 2011; 31 (7) 678-685
• 35 McLintock C. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart valves. Best Pract Res Clin Obstet Gynaecol 2014; 28 (4) 519-536
• 36 Wigle P, Hein B, Bloomfield HE, Tubb M, Doherty M. Updated guidelines on outpatient anticoagulation. Am Fam Physician 2013; 87 (8) 556-566
• 37 Funk DM. Coagulation assays and anticoagulant monitoring. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 460-465
• 38 Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21 (2) 218-234
• 39 Stratta P, Karvela E, Canavese C , et al. Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure. Curr Med Chem 2009; 16 (23) 3028-3040
• 40 Anti-Xa assays . Available at: http://practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/anti_xa_assays.html . Accessed April 29, 2012
• 41 Bates SM, Weitz JI. Coagulation assays. Circulation 2005; 112 (4) e53-e60
• 42 TECHNOCHROM®anti-Xa (AT+) ⋄TECHNOCHROM®anti-Xa . Available at: http://www.technoclone.com/pdf/folder/files/C002C-003_Technochrom%20anti-xa.pdf . Accessed May 24, 2016
• 43 Dempfle CE, Zharkowa U, Elmas E, Ahmad-Nejad P, Neumaier M, Borggrefe M. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma. Thromb Haemost 2009; 102 (5) 1001-1006
• 44 Campbell PJ, Tirvengadum MA, Pickering W, Cohen H, Ryan KE. HEPTEST: a suitable method for monitoring heparin during pregnancy. Clin Lab Haematol 1999; 21 (3) 193-199
• 45 Thomas O, Lybeck E, Strandberg K, Tynngård N, Schött U. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS ONE 2015; 10 (1) e0116835
• 46 Blombäck M, Bremme K, Hellgren M, Siegbahn A, Lindberg H. Thromboprophylaxis with low molecular mass heparin, ‘Fragmin’ (dalteparin), during pregnancy—a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 9 (1) 1-9
• 47 Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181 (5 Pt 1): 1113-1117
• 48 Hunt BJ, Doughty HA, Majumdar G , et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77 (1) 39-43
• 49 O'Connell MP, O'Leary M, MacKeogh L, Murphy K, Keane DP. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?. Eur J Obstet Gynecol Reprod Biol 2004; 114 (1) 12-14
• 50 Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost 2004; 92 (4) 791-796
• 51 Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ ; British Society for Haematology Obstetric Haematology Group. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007; 139 (4) 545-558
• 52 Macafee B, Campbell JP, Ashpole K , et al. Reference ranges for thromboelastography (TEG(®) ) and traditional coagulation tests in term parturients undergoing caesarean section under spinal anaesthesia*. Anaesthesia 2012; 67 (7) 741-747
• 53 Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002; 107 (5) 241-244
• 54 Hofmann M, Rest A, Hafner G, Tanner B, Brockerhoff P, Weilemann LS. D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders [in German]. Anaesthesist 1997; 46 (8) 689-696
• 55 Han L, Liu X, Li H , et al. Blood coagulation parameters and platelet indices: changes in normal and preeclamptic pregnancies and predictive values for preeclampsia. PLoS ONE 2014; 9 (12) e114488
• 56 Francis CW, Marder VJ. A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost 1982; 8 (1) 25-35
• 57 Kubisz P, Staško J. Hematológia a transfuziológia. 1st ed. Bratislava, Praha: Grada Slovakia—Grada, Publishing; 2006: 159-216
• 58 Ciesla B. Hematology in Practice. 2nd ed. Philadelphia, PA: F. A. Davis Company; 2012: 231-296 , 316–321
• 59 Moresco RN, Vargas LC, Voegeli CF, Santos RC. D-dimer and its relationship to fibrinogen/fibrin degradation products (FDPs) in disorders associated with activation of coagulation or fibrinolytic systems. J Clin Lab Anal 2003; 17 (3) 77-79
• 60 Lippi G, Montagnana M. D-dimer testing in pregnancy: clinically useful, but at what cost?. Ann Intern Med 2008; 148 (6) 484 , author reply 484–485
• 61 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59 (1) 101-106
• 62 Schinzel H, Bahlmann F, Peetz D, Savvidis S, Himmrich L, Klotz M. Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy [in German]. Med Klin (Munich) 2002; 97 (4) 193-203
• 63 Reinthaller A, Mursch-Edlmayr G, Tatra G. Thrombin-antithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynaecol 1990; 97 (6) 506-510
• 64 Hackney DN, Catov JM, Simhan HN. Low concentrations of thrombin-inhibitor complexes and the risk of preterm delivery. Am J Obstet Gynecol 2010; 203 (2) 184.e1-184.e6
• 65 Hackney DN, Chiao JP, Macpherson TA, Simhan HN. First trimester maternal concentrations of thrombin-inhibitor complexes and the presence of histologic placental lesions at delivery. J Matern Fetal Neonatal Med 2009; 22 (10) 837-842
• 66 Vidaeff AC, Monga M, Saade G, Bishop K, Ramin SM. Prospective investigation of second-trimester thrombin activation and preterm birth. Am J Obstet Gynecol 2012; 206 (4) 333.e1-333.e6
• 67 Guven S, Sonmez M, Karahan SC. The role of fibrinolytic and antifibrinolytic activities in the pathophysiology of HELLP syndrome. Hypertens Pregnancy 2011; 30 (3) 275-286
• 68 Erez O, Gotsch F, Mazaki-Tovi S , et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med 2009; 22 (8) 672-687
• 69 Catov JM, Bodnar LM, Hackney D, Roberts JM, Simhan HN. Activation of the fibrinolytic cascade early in pregnancy among women with spontaneous preterm birth. Obstet Gynecol 2008; 112 (5) 1116-1122
• 70 Chaiworapongsa T, Yoshimatsu J, Espinoza J , et al. Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002; 11 (6) 362-367
• 71 Chaiworapongsa T, Espinoza J, Yoshimatsu J , et al. Activation of coagulation system in preterm labor and preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002; 11 (6) 368-373
• 72 Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ. Plasma levels of thrombin-antithrombin complexes predict preterm premature rupture of the fetal membranes. J Matern Fetal Med 2001; 10 (5) 297-300
• 73 Schjetlein R, Haugen G, Wisløff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997; 76 (6) 541-546
• 74 Lancé MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J 2015; 13: 1
• 75 Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. J Thromb Haemost 2004; 2 (8) 1299-1304
• 76 Bombeli T, Raddatz Mueller P, Fehr J. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers. Haemostasis 2001; 31 (2) 90-98
• 77 Patel JP, Patel RK, Roberts LN , et al. Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium. BMC Pregnancy Childbirth 2014; 14: 384
• 78 McLean KC, Bernstein IM, Brummel-Ziedins KE. Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol 2012; 207 (2) 135.e1-135.e6
• 79 Chowdary P, Adamidou D, Riddell A , et al. Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring. Br J Haematol 2015; 168 (5) 719-727
• 80 Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89 (2) 228-232
• 81 Collins NF, Bloor M, McDonnell NJ. Hyperfibrinolysis diagnosed by rotational thromboelastometry in a case of suspected amniotic fluid embolism. Int J Obstet Anesth 2013; 22 (1) 71-76
• 82 Solomon C, Schöchl H, Ranucci M, Schött U, Schlimp CJ. Comparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox ®) versus thromboelastometry (ROTEM ®). Scand J Clin Lab Invest 2015; 75 (3) 239-246
• 83 ROTEM® analysis. Thromboelastometry. Available at: http://www.rotem.de/en/methodology/rotem-analysis/ . Accessed May 24, 2016
• 84 Lang T, von Depka M. Possibilities and limitations of thromboelastometry/thromboelastography. Hamostaseologie 2006; 26 (3) (Suppl. 01) S20-S29
• 85 ROTEM® reagents . Available at: http://www.rotem.de/en/products/reagents/ . Accessed May 24, 2016
• 86 Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106 (5) 1366-1375
• 87 Hunt H, Stanworth S, Curry N , et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2015; 2: CD010438
• 88 Oswald E, Velik-Salchner C, Innerhofer P , et al. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study. Blood Coagul Fibrinolysis 2015; 26 (2) 136-144
• 89 Grassetto A, Saggioro D, Caputo P , et al. Rotational thromboelastometry analysis and management of life-threatening haemorrhage in isolated craniofacial injury. Blood Coagul Fibrinolysis 2012; 23 (6) 551-555
• 90 McNamara H, Mallaiah S, Barclay P, Chevannes C, Bhalla A. Coagulopathy and placental abruption: changing management with ROTEM-guided fibrinogen concentrate therapy. Int J Obstet Anesth 2015; 24 (2) 174-179
• 91 Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth 2012; 109 (6) 851-863
• 92 Rath WH, Hoferr S, Sinicina I. Amniotic fluid embolism: an interdisciplinary challenge: epidemiology, diagnosis and treatment. Dtsch Arztebl Int 2014; 111 (8) 126-132
• 93 de Lange NM, Lancé MD, de Groot R, Beckers EA, Henskens YM, Scheepers HC. Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv 2012; 67 (7) 426-435
• 94 van Rheenen-Flach LE, Zweegman S, Boersma F, Lenglet JE, Twisk JWR, Bolte AC. A prospective longitudinal study on rotation thromboelastometry in women with uncomplicated pregnancies and postpartum. Aust N Z J Obstet Gynaecol 2013; 53 (1) 32-36
• 95 Huissoud C, Carrabin N, Benchaib M , et al. Coagulation assessment by rotation thrombelastometry in normal pregnancy. Thromb Haemost 2009; 101 (4) 755-761
• 96 Staško J, Duraj L, Haško M , et al. Is rotation thromboelastometry a useful method for monitoring of hemostasis in normal pregnancy and puerperium?. ISTH 2013; 4: 65-5